跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XALKORI 150 MG GRANULADO EN CAPSULAS PARA ABRIR - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
XALKORI 150 MG GRANULADO EN CAPSULAS PARA ABRIR
Approved
STANDARD
XALKORI 150 MG GRANULADO EN CAPSULAS PARA ABRIR
Pfizer Europe Ma Eeig
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Sep 20, 2024
Approval ID
84fda6f228c90b6c
Company
Pfizer Europe Ma Eeig
Type
Standard
Approval Details
Approval Id
84fda6f228c90b6c
Drug Cima Aemps Name
XALKORI 150 MG GRANULADO EN CAPSULAS PARA ABRIR
Register Number
112793007
Holder Company Name
Pfizer Europe Ma Eeig
Marketing Company Name
Pfizer S.L.
Holder Company Detail Path
/organization/pfizer-europe-ma-eeig
Authorization Date
2024-09-20
Dosage Form
GRANULADO EN CAPSULAS PARA ABRIR
Dose
150 mg
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Pfizer Europe Ma Eeig
Company Detail Path
/organization/pfizer-europe-ma-eeig
Company Information
Pharmaceutical Company Name
Pfizer Europe MA EEIG
Country Name
United Kingdom
Active Ingredients
CRIZOTINIB
150 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Sep 20, 2024
Approval ID
84fda6f228c90b6c
Type
Standard
Back to CIMA-AEMPS Approvals
